heart ecg arrhythmia The FDA has approved the Prior Approval Supplement for Bretylium Tosylate Injection, allowing ANI Pharmaceuticals to market the once discontinued antiarrhythmic agent. The Food ...

Atrial fibrillation is the most common type of cardiac arrhythmia, and is a common cause of stroke and heart failure. Currently, there is a major unmet need for drugs that are capable of successfully ...

Background: Of the antiarrhythmic agents currently marketed in Canada, 5 are commonly used to treat atrial fibrillation (AF). The impact of contraindications, warnings and precautions for the use of ...

The batch was distributed between August 14, 2018 and September 5, 2018. Nexterone is a prescription antiarrhythmic agent indicated for initiation of treatment and prophylaxis of frequently recurring ...